Aducanumab and disease modifying treatments for Alzheimer's disease

Thomas, Elaine R.; Wasunna-Smith, Brenda; Kuruvilla, Tarun

doi:10.1002/pnp.711

Cited by 8 publications

(8 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 5 Expectations for the therapeutic effects of recently developed amyloid-modifying drugs on MCI are emerging. 6 , 7 These underscore the necessity of public health initiatives to promote early screening for cognitive impairment in the elderly, particularly those utilizing primary care medical facilities in the community.…”

Section: Introductionmentioning

confidence: 99%

Assessment of Mild Cognitive Impairment Using CogEvo: A Computerized Cognitive Function Assessment Tool

Satoh,

Sawada,

Saba

et al. 2024

J Prim Care Community Health

View full text Add to dashboard Cite

Introduction/Objectives: To assess the utility of the computerized cognitive function assessment tool, CogEvo, as a screening tool for mild cognitive impairment in primary care, we explored the relationship between CogEvo performance, age, and the severity of cognitive dysfunction evaluated by the Mini-Mental State Examination (MMSE). Methods: The observational cross-sectional study included 209 individuals’ data (mean age 79.4 ± 8.9 years). We conducted a correlation analysis between CogEvo and MMSE scores, compared the performance among the 3 cognitive function groups (MMSE ≥ 28 group; MMSE24-27 group; MMSE ≤ 23 group) using the MMSE cut-off, and evaluated CogEvo’s predictive accuracy for cognitive dysfunction through ROC analysis. Results: Both total CogEvo and MMSE scores significantly decreased with age. A significant positive correlation was observed between total CogEvo and MMSE scores, but a ceiling effect was detected in MMSE performance. Significant differences were observed in the total CogEvo score, including orientation and spatial cognitive function scores, among the 3 groups. CogEvo showed no educational bias. ROC analyses indicated moderate discrimination between the MMSE ≥ 28 group and the MMSE24-27 and MMSE ≤ 23 groups. Conclusions: The computer-administered CogEvo has the advantage of not exhibiting ceiling effects or educational bias like the MMSE, and was found to be able to detect age-related cognitive decline and impairment.

show abstract

Section: Introductionmentioning

confidence: 99%

Assessment of Mild Cognitive Impairment Using CogEvo: A Computerized Cognitive Function Assessment Tool

Satoh,

Sawada,

Saba

et al. 2024

J Prim Care Community Health

View full text Add to dashboard Cite

show abstract

“…Recently, new amyloid disease modifiers that control progression have been developed. [2][3][4] The first step in diagnosing cognitive dysfunction is to identify mild cognitive impairment (MCI) or the cognitively normal (CN) before the onset of AD, and then begin the treatment accordingly. [4][5][6] So far, the Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) have been known as the neuropsychological tests that detect cognitive decline and sensitively discriminate between MCI and AD.…”

Section: Introductionmentioning

confidence: 99%

“…Drugs that improve the symptoms have been used in such cases to suppress exacerbation and delay the progression of cognitive dysfunction. Recently, new amyloid disease modifiers that control progression have been developed 2–4 . The first step in diagnosing cognitive dysfunction is to identify mild cognitive impairment (MCI) or the cognitively normal (CN) before the onset of AD, and then begin the treatment accordingly 4–6 …”

Section: Introductionmentioning

confidence: 99%

Validity and reliability of a computerized cognitive function evaluation battery (CogEvo) as a screening tool

Sawada

Satoh²,

Saba³

et al. 2023

PCN Reports

View full text Add to dashboard Cite

Aim:The aim of this study was to determine the validity and reliability of cognitive function evaluation battery, CogEvo, a recently developed computerized cognitive function evaluation battery, as a screening tool for decreased cognitive function. Methods:The study sample comprised 123 (age: 57-97 years) community-dwelling elderly people. They were required to perform five CogEvo tasks and complete two questions-based neuropsychological tests, including the Mini-Mental State Examination, so that the correlations could be analyzed. The validity and reliability of CogEvo were examined using factor analysis, MacDonald's omega reliability coefficient, logistic regression analysis, and receiver operating characteristic curve analysis.Results: Exploratory factor analysis revealed the orientation/spatial cognitive function (orientation and spatial cognition) and attention/executive function (attention, memory, and execution) factors. Structural validity was supported by confirmatory factor analysis.All two-factor-based subtasks showed adequate internal consistency (MacDonald's omega ≥0.6). The total CogEvo score and two-factor scores were significantly correlated with neuropsychological test results. Based on the total CogEvo score, the cognitively normal and cognitive decline groups were identified by receiver operating characteristic curve analysis with a moderate predictive performance. The cognitive decline group was well identified using the orientation/spatial cognitive function factor.Conclusions: CogEvo is a valid and reliable screening tool for cognitive function evaluation. It proved useful in the early identification of cognitive decline in our study sample.

show abstract

“…Diagnosis is based on a combination of cognitive and memory testing; brain imaging, particularly PET to detect increased β-amyloid and MRI to detect atrophy; and lumbar puncture identify β-amyloid and tau in the cerebrospinal fluid (CSF) ( Bird et al, 2010 ; Clarke et al, 2018 ; Alzheimer’s Association, 2020 ). To date, only the recently approved anti-amyloid monoclonal antibody, Aducanumab, has showed potential to treat AD, and requires more time to determine efficacy ( Thomas et al, 2021 ). Despite its controversy, no other pharmacological treatments have demonstrated efficacy to slow or stop the neuronal destruction in AD ( Alzheimer’s Association, 2020 ).…”

Section: Introductionmentioning

confidence: 99%

Preserved Consciousness in Alzheimer’s Disease and Other Dementias: Caregiver Awareness and Communication Strategies

Warren

2021

Front. Psychol.

View full text Add to dashboard Cite

Alzheimer’s disease is an insidious onset neurodegenerative syndrome without effective treatment or cure. It is rapidly becoming a global health crisis that is overwhelming healthcare, society, and individuals. The clinical nature of neurocognitive decline creates significant challenges in bidirectional communication between caregivers and persons with Alzheimer’s disease (AD) that can negatively impact quality-of-life. This paper sought to understand how and to what extent would awareness training about the levels of consciousness in AD influence the quality-of-life interactions in the caregiver-patient dyad. A literature review of multiple databases was conducted utilizing a transdisciplinary approach. The sum of findings indicates a positive relationship between enhanced caregiver awareness and training, positive interactions, and improved QOL measures among patients and caregivers. A multidirectional relationship was found among healthcare policies, training and education resources, caregivers, and persons with AD. Specifically, the current lack of policy and inadequate training and educational resources has various detrimental effects on patients and caregivers, while improvements in training and education of caregivers yields positive outcomes in communication and QOL. Furthermore, evidence of preserved consciousness in persons with AD was demonstrated from multiple disciplines, including neurobiological, psychological, and biopsychosocial models. The literature further revealed several methods to access the preserved consciousness in persons with AD and related dementias, including sensory, emotional, and cognitive stimulations. The evidence from the literature suggests a reframed approach to our understanding and treatment of persons with AD is not only warranted, but crucial to address the needs of those affected by AD.

show abstract

Aducanumab and disease modifying treatments for Alzheimer's disease

Cited by 8 publications

References 14 publications

Assessment of Mild Cognitive Impairment Using CogEvo: A Computerized Cognitive Function Assessment Tool

Assessment of Mild Cognitive Impairment Using CogEvo: A Computerized Cognitive Function Assessment Tool

Validity and reliability of a computerized cognitive function evaluation battery (CogEvo) as a screening tool

Preserved Consciousness in Alzheimer’s Disease and Other Dementias: Caregiver Awareness and Communication Strategies

Contact Info

Product

Resources

About